The future of Sanofi and Lexicon’s oral diabetes drug Zynquista hangs in the balance after an FDA advisory committee was split on whether the drug would benefit patients.
Sanofi and Regeneron have restructured and extended their immune-oncology discovery and development agreement, giving the French drugmaker rights to opt-in to development and marketing of t
Sanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent price cut, a new study has claimed.
Sanofi and Merck & Co picked up late 2018 approval from the FDA during the holiday period, getting a green light for their six-in-one paediatric shot Vaxelis.
Boehringer Ingelheim has confirmed it plans to axe more than 10% of its workforce in France, or more than 300 jobs, adding to several hundred losses at Sanofi last week.